The BYL719 (PI3Kα specific inhibitor), namely Alpelisib (123) and the Copanlisib (highly selective, pan-class I PI3K inhibitors) (120), are shown to improve CTX-induced tumor inhibition in HNSCC CTX-resistant cell lines and PDX. The gene discussed is PIK3CA; the disease is head and neck squamous cell carcinoma.